Summary
In November 2004, the Austrian Society of Gastroenterology and Hepatology (ÖGGH) held for the first time a consensus meeting on the definitions and treatment of portal hypertension and its complications in the Billroth-Haus in Vienna, Austria (Billroth I-Meeting). This meeting was preceded by a meeting of international experts on portal hypertension with some of the proponents of the Baveno consensus conferences (http://www.oeggh.at/videos.asp). The consensus itself is based on the Baveno III consensus with regard to portal hypertensive bleeding and the suggestions of the International Ascites Club regarding the treatment of ascites. Those statements were modified by new knowledge derived from the recent literature and also by the current practice of medicine as agreed upon by the participants of the consensus meeting. In October 2011, the ÖGGH organized the second consensus meeting on portal hypertension and its complications in Vienna (Billroth II-Meeting). The Billroth II-Guidelines on the definitions and treatment of portal hypertension and its complications take into account the developments of the last 7 years, including the Baveno-V update and several key publications.
Zusammenfassung
Im November 2004 hielt die Österreichische Gesellschaft für Gastroenterologie und Hepatologie (ÖGGH) den ersten Konsensus über die Definitionen und die Therapie der Portalen Hypertension und ihrer Komplikationen im Billroth-Haus in Wien, Österreich ab (Billroth I Meeting). Diesem Treffen ging ein internationales Expertenmeeting über die Portale Hypertension mit einigen wichtigen Proponenten der Baveno Konsensus-Konferenzen vorraus (http://www.oeggh.at/videos.asp). Der Konsensus selber basiert auf dem Baveno III Konsensus im Hinblick auf die portal-hypertensive Blutung und den Vorschlägen des International Ascites Club in Hinblick auf die Therapie des Aszites. Deren Aussagen wurden mit neuen Erkenntnissen aus der rezenten Literatur und auch entsprechend der praktischen Erfahrung der Teilnehmer des Konsensus-Treffens modifiziert. Im Oktober 2001 organisierte die ÖGGH das zweite Konsensus Treffen über die portale Hypertension und ihrer Komplikationen (Billroth II Meeting). Die Billroth II Leitlinien über die Definitionen und die Therapie der Portalen Hypertension und ihrer Komplikationen lassen die Entwicklungen der letzten 7 Jahre inklusive des Baveno V Updates und etlicher Schlüsselpublikationen mit einfließen und stellen den neuen Standard im Management der Portalen Hypertension in Österreich dar.
Abbreviations
- AVB:
-
Acute variceal bleeding
- BCS:
-
Budd-Chiari syndrome
- CSPH:
-
Clinically significant portal hypertension
- FCB:
-
Failure to control bleeding
- FFP:
-
Fresh frozen plasma
- GAVE:
-
Gastric antral vascular ectasia
- GOV:
-
Gastro oesophageal varices
- HCC:
-
Hepatocellular carcinoma
- HE:
-
Hepatic encephalopathy
- HPS:
-
Hepatopulmonary syndrome
- HRS:
-
Hepatorenal syndrome
- HVPG:
-
Hepatovenous pressure gradient
- IGV:
-
Isolated gastric varices
- ISMN:
-
Isosorbidmononitrate
- NSBB:
-
Nonselective beta-blockers
- PPHTN:
-
Portopulmonary hypertension
- PTFE:
-
Polytetrafluoroethylene
- PHG:
-
Portal hypertensive gastropathy
- TIPS:
-
Transjugular intrahepatic portosystemic stent
- SBP:
-
Spontaneous bacterial peritonitis
References
de Franchis R. Updating consensus in portal hypertension: report of the Baveno III consensus workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol. 2000;33:846–52.
Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, Angeli P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology. 2003;38:258–66.
Angermayr B, Cejna M, Peck-Radosavljevic M. Management von Patienten vor und nach Implantation eines transjugulären intrahepatischen portosystemischen Shunts (TIPS) – Bericht der Vienna TIPS Study Group. Journal für Gastroenterologische und Hepatologische Erkrankungen. 2003;1:11–4.
de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010;53:762–8.
EASL. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245–64.
Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. portal hypertension. J Hepatol. 2000;32:141–56.
Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, Escorsell A, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005;353:2254–61.
Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology. 1985;5:419–24.
D’Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis. 1999;19:475–505.
Tripathi D, Ferguson JW, Kochar N, Leithead JA, Therapondos G, McAvoy NC, Stanley AJ, et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology. 2009;50:825–33.
Imperiale TF, Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Hepatology. 2001;33:802–7.
Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Bellini B, Bighin R, Gatta A. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology. 2000;32:930–4.
Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology. 2003;37:902–8.
Tripathi D, Hayes PC. The role of carvedilol in the management of portal hypertension. Eur J Gastroenterol Hepatol. 2010;22:905–11.
Bosch J. Carvedilol for portal hypertension in patients with cirrhosis. Hepatology. 2010;51:2214–8.
Turnes J, Garcia-Pagan JC, Abraldes JG, Hernandez-Guerra M, Dell’Era A, Bosch J. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am J Gastroenterol. 2006;101:506–12.
D’Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology. 2006;131:1611–24.
D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217–31.
Banares R, Moitinho E, Matilla A, Garcia-Pagan JC, Lampreave JL, Piera C, Abraldes JG, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology. 2002;36:1367–73.
Reiberger T, Ulbrich G, Ferlitsch A, Payer BA, Pinter M, Peck-Radosavljevic M. Carvedilol for prophylaxis of variceal bleeding in cirrhotic patients with hemodynamic non-response to propranolol. Hepatology. 2010;52 (Suppl 1):A21.
Garcia-Pagan JC, Morillas R, Banares R, Albillos A, Villanueva C, Vila C, Genesca J, et al. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT. Hepatology. 2003;37:1260–6.
Ben-Ari Z, Cardin F, McCormick AP, Wannamethee G, Burroughs AK. A predictive model for failure to control bleeding during acute variceal haemorrhage. J Hepatol. 1999;31:443–50.
Bernard B, Grange JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology. 1999;29:1655–61.
Moitinho E, Escorsell A, Bandi JC, Salmeron JM, Garcia-Pagan JC, Rodes J, Bosch J. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology. 1999;117:626–31.
Hubmann R, Bodlaj G, Czompo M, Benko L, Pichler P, Al-Kathib S, Kiblbock P, et al. The use of self-expanding metal stents to treat acute esophageal variceal bleeding. Endoscopy. 2006;38:896–901.
Monescillo A, Martinez-Lagares F, Ruiz-del-Arbol L, Sierra A, Guevara C, Jimenez E, Marrero JM, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology. 2004;40:793–801.
Garcia-Pagan JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, Abraldes JG, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010;362:2370–9.
Bureau C, Peron JM, Alric L, Morales J, Sanchez J, Barange K, Payen JL, et al. “A La Carte” treatment of portal hypertension: adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology. 2002;36:1361–6.
Primignani M, Carpinelli L, Preatoni P, Battaglia G, Carta A, Prada A, Cestari R, et al. Natural history of portal hypertensive gastropathy in patients with liver cirrhosis. The New Italian Endoscopic Club for the study and treatment of esophageal varices (NIEC). Gastroenterology. 2000;119:181–7.
Stewart CA, Sanyal AJ. Grading portal gastropathy: validation of a gastropathy scoring system. Am J Gastroenterol. 2003;98:1758–65.
Ward EM, Raimondo M, Rosser BG, Wallace MB, Dickson RD. Prevalence and natural history of gastric antral vascular ectasia in patients undergoing orthotopic liver transplantation. J Clin Gastroenterol. 2004;38:898–900.
Sarin SK, Lahoti D, Saxena SP, Murthy NS, Makwana UK. Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients. Hepatology. 1992;16:1343–9.
Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46:922–38.
Lo GH, Lai KH, Cheng JS, Chen MH, Chiang HT. A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. Hepatology. 2001;33:1060–4.
Sarin SK, Jain AK, Jain M, Gupta R. A randomized controlled trial of cyanoacrylate versus alcohol injection in patients with isolated fundic varices. Am J Gastroenterol. 2002;97:1010–5.
Tan PC, Hou MC, Lin HC, Liu TT, Lee FY, Chang FY, Lee SD. A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-butyl-2-cyanoacrylate injection versus band ligation. Hepatology. 2006;43:690–7.
Kang EJ, Jeong SW, Jang JY, Cho JY, Lee SH, Kim HG, Kim SG, et al. Long-term result of endoscopic histoacryl (N-butyl-2-cyanoacrylate) injection for treatment of gastric varices. World J Gastroenterol. 2011;17:1494–1500.
Seewald S, Ang TL, Imazu H, Naga M, Omar S, Groth S, Seitz U, et al. A standardized injection technique and regimen ensures success and safety of N-butyl-2-cyanoacrylate injection for the treatment of gastric fundal varices (with videos). Gastrointest Endosc. 2008;68:447–54.
Akahoshi T, Hashizume M, Shimabukuro R, Tanoue K, Tomikawa M, Okita K, Gotoh N, et al. Long-term results of endoscopic histoacryl injection sclerotherapy for gastric variceal bleeding: a 10-year experience. Surgery. 2002;131:S176–81.
Kumamoto M, Toyonaga A, Inoue H, Miyakoda K, Morita Y, Emori K, Sakamoto Y, et al. Long-term results of balloon-occluded retrograde transvenous obliteration for gastric fundal varices: hepatic deterioration links to portosystemic shunt syndrome. J Gastroenterol Hepatol. 2010;25:1129–35.
Hiraga N, Aikata H, Takaki S, Kodama H, Shirakawa H, Imamura M, Kawakami Y, et al. The long-term outcome of patients with bleeding gastric varices after balloon-occluded retrograde transvenous obliteration. J Gastroenterol. 2007;42:663–72.
Arai H, Abe T, Takagi H, Mori M. Efficacy of balloon-occluded retrograde transvenous obliteration, percutaneous transhepatic obliteration and combined techniques for the management of gastric fundal varices. World J Gastroenterol. 2006;12:3866–73.
Chau TN, Patch D, Chan YW, Nagral A, Dick R, Burroughs AK. “Salvage” transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding (see comments). Gastroenterology. 1998;114:981–7.
Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: update 2009. Hepatology. 2010;51:306.
Pache I, Bilodeau M. Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease. Aliment Pharmacol Ther. 2005;21:525–9.
Boyer TD, Zia P, Reynolds TB. Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology. 1979;77:215–22.
Pariente EA, Bataille C, Bercoff E, Lebrec D. Acute effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites. Gastroenterology. 1985;88:1255–9.
Gentilini P, Romanelli RG, La Villa G, Maggiore Q, Pesciullesi E, Cappelli G, Casini Raggi V, et al. Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver. Gastroenterology. 1993;104:588–94.
Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med. 2004;350:1646–54.
EASL. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397–417.
Rimola A, Garcia-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, Inadomi JM. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol. 2000;32:142–53.
Nguyen-Khac E, Cadranel JF, Thevenot T, Nousbaum JB. Review article: the utility of reagent strips in the diagnosis of infected ascites in cirrhotic patients. Aliment Pharmacol Ther. 2008;28:282–8.
Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, Castells L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341:403–9.
Han G, Qi X, He C, Yin Z, Wang J, Xia J, Yang Z, et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. J Hepatol. 2011;54:78–88.
Rautou PE, Angermayr B, Garcia-Pagan JC, Moucari R, Peck-Radosavljevic M, Raffa S, Bernuau J, et al. Pregnancy in women with known and treated Budd-Chiari syndrome: maternal and fetal outcomes. J Hepatol. 2009;51:47–54.
Garcia-Pagan JC, Heydtmann M, Raffa S, Plessier A, Murad S, Fabris F, Vizzini G, et al. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology. 2008;135:808–15.
Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23:164–76.
Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56:1310–8.
Krag A, Bendtsen F, Henriksen JH, Moller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut. 2010;59:105–10.
Rajekar H, Chawla Y. Terlipressin in hepatorenal syndrome: evidence for present indications. J Gastroenterol Hepatol. 2011;26 Suppl 1:109–14.
Sagi SV, Mittal S, Kasturi KS, Sood GK. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol. 2010;25:880–5.
Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology. 2010;51:576–84.
Gerbes AL, Gulberg V, Sauerbruch T, Wiest R, Appenrodt B, Bahr MJ, Dollinger MM, et al. (German S 3-Guideline “ascites, spontaneous bacterial peritonitis, hepatorenal syndrome”). Z Gastroenterol. 2011;49:749–79.
Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008;134:1360–8.
Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L, Siringo S, et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci. 2008;53:830–5.
Martin-Llahi M, Pepin MN, Guevara M, Diaz F, Torre A, Monescillo A, Soriano G, et al. Terlipressin and albumin vs. albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008;134:1352–9.
Piano S, Morando F, Fasolato S, Cavallin M, Boscato N, Boccagni P, Zanus G, et al. Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation? J Hepatol. 2011;55:491–6.
Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, Teuber P. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol. 2011;55:315–21.
Salerno F, Cazzaniga M, Merli M, Spinzi G, Saibeni S, Salmi A, Fagiuoli S, et al. Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice. J Hepatol. 2011;55(6):124–8.
Gerbes AL, Huber E, Gulberg V. Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration. Gastroenterology. 2009;137: 1179–81.
Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol. 2008;103:1689–97.
Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004;40:55–64.
Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, Amodio P, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999;29:1690–7.
Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las Heras D, Guevara M, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology. 2002;36:941–8.
Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, Klehr HU, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut. 2000;47:288–95.
Guevara M, Gines P, Bandi JC, Gilabert R, Sort P, Jimenez W, Garcia-Pagan JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems (see comments). Hepatology. 1998;28:416–22.
Rossle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut. 2010;59:988–1000.
Rifai K, Kribben A, Gerken G, Haag S, Herget-Rosenthal S, Treichel U, Betz C, et al. Extracorporeal liver support by fractionated plasma separation and adsorption (Prometheus) in patients with acute-on-chronic liver failure (HELIOS study): a prospective randomized controlled multicenter study. J Hepatol. 2010;52:6A.
Banares R, Nevens F, Larsen FS, Jalan R, Albillos A, Dollinger M. Relief Study Group. Extracorporeal liver support with the molecular absorbent recirculating system (MARS) in patients with acute-on-chronic liver failure (AOCLF). The RELIEF trial. J Hepatol. 2010;52:1184A.
Charlton MR, Wall WJ, Ojo AO, Gines P, Textor S, Shihab FS, Marotta P, et al. Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl. 2009;15:S1–34.
Fernandez J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, Vila C, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007;133:818–24.
Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:1637–48.
Lebrec D, Thabut D, Oberti F, Perarnau JM, Condat B, Barraud H, Saliba F, et al. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology. 2010;138:1755–62.
Ogren M, Bergqvist D, Bjorck M, Acosta S, Eriksson H, Sternby NH. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol. 2006;12:2115–9.
Ogren M, Bergqvist D, Bjorck M, Acosta S, Sternby NH. High incidence of concomitant venous thromboembolism in patients with portal vein thrombosis: a population study based on 23,796 consecutive autopsies. J Thromb Haemost. 2007;5:198–200.
Sarin SK, Sollano JD, Chawla YK, Amarapurkar D, Hamid S, Hashizume M, Jafri W, et al. Consensus on extra-hepatic portal vein obstruction. Liver Int. 2006;26:512–19.
Janssen HL, Garcia-Pagan JC, Elias E, Mentha G, Hadengue A, Valla DC. Budd-Chiari syndrome: a review by an expert panel. J. Hepatol. 2003;38:364–71.
de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J. Hepatol. 2010;53:762–8.
Rajani R, Melin T, Bjornsson E, Broome U, Sangfelt P, Danielsson A, Gustavsson A, et al. Budd-Chiari syndrome in Sweden: epidemiology, clinical characteristics and survival—an 18-year experience. Liver Int. 2009;29:253–9.
Smalberg JH, Koehler E, Darwish Murad S, Plessier A, Seijo S, Trebicka J, Primignani M, et al. The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis. Blood. 2011;117:3968–73.
Xavier SG, Gadelha T, Pimenta G, Eugenio AM, Ribeiro DD, Gomes FM, Bonamino M, et al. JAK2V617F mutation in patients with splanchnic vein thrombosis. Dig Dis Sci. 2010;55:1770–7.
Tondeur S, Boutruche S, Biron-Andreani C, Schved JF. Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study. Thromb Haemost. 2009;101:787–9.
Colaizzo D, Amitrano L, Tiscia GL, Scenna G, Grandone E, Guardascione MA, Brancaccio V, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost. 2007;5:55–61.
Carreras E, Bertz H, Arcese W, Vernant JP, Tomas JF, Hagglund H, Bandini G, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European group for blood and marrow transplantation. European group for blood and marrow transplantation chronic leukemia working party. Blood. 1998;92:3599–604.
Deleve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology. 2009;49:1729–64.
Tsochatzis EA, Senzolo M, Germani G, Gatt A, Burroughs AK. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther. 2010;31:366–74.
Hoekstra J, Janssen HL. Vascular liver disorders (I): diagnosis, treatment and prognosis of Budd-Chiari syndrome. Neth J Med. 2008;66:334–9.
Hoekstra J, Janssen HL. Vascular liver disorders (II): portal vein thrombosis. Neth J Med. 2009;67:46–53.
Crawford JM. Vascular disorders of the liver. Clin Liver Dis. 2010;14:635–50.
Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493–537.
Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB. Pulmonary-Hepatic vascular disorders (PHD). Eur Respir J. 2004;24:861–80.
Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology. 1991;100:520–8.
Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, Mal H, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology. 2003;37:401–9.
Benjaminov FS, Prentice M, Sniderman KW, Siu S, Liu P, Wong F. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut. 2003;52:1355–62.
Ramsay MA, Simpson BR, Nguyen AT, Ramsay KJ, East C, Klintmalm GB. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg. 1997;3:494–500.
Taura P, Garcia-Valdecasas JC, Beltran J, Izquierdo E, Navasa M, Sala-Blanch J, Mas A, et al. Moderate primary pulmonary hypertension in patients undergoing liver transplantation. Anesth Analg. 1996;83:675–80.
Castro M, Krowka MJ, Schroeder DR, Beck KC, Plevak DJ, Rettke SR, Cortese DA, et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. Mayo Clin Proc. 1996;71:543–51.
Plevak D, Krowka M, Rettke S, Dunn W, Southorn P. Successful liver transplantation in patients with mild to moderate pulmonary hypertension. Transplant Proc. 1993;25:1840.
Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol. 1991;17:492–8.
McLaughlin VV, Genthner DE, Panella MM, Hess DM, Rich S. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med. 1999;130:740–3.
Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology. 1999;30:641–8.
Hoeper MM, Seyfarth HJ, Hoeffken G, Wirtz H, Spiekerkoetter E, Pletz MW, Welte T, et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J. 2007;30:1096–102.
Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, Niedermeyer J, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J. 2005;25:502–8.
Tan HP, Markowitz JS, Montgomery RA, Merritt WT, Klein AS, Thuluvath PJ, Poordad FF, et al. Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol. Liver Transpl. 2001;7:745–9.
Kett DH, Acosta RC, Campos MA, Rodriguez MJ, Quartin AA, Schein RM. Recurrent portopulmonary hypertension after liver transplantation: management with epoprostenol and resolution after retransplantation. Liver Transpl. 2001;7:645–8.
Plotkin JS, Kuo PC, Rubin LJ, Gaine S, Howell CD, Laurin J, Njoku MJ, et al. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation. 1998;65:457–9.
Ashfaq M, Chinnakotla S, Rogers L, Ausloos K, Saadeh S, Klintmalm GB, Ramsay M, et al. The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant. 2007;7:1258–64.
Reichenberger F, Voswinckel R, Steveling E, Enke B, Kreckel A, Olschewski H, Grimminger F, et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J. 2006;28:563–7.
Kuntzen C, Gulberg V, Gerbes AL. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy? Gastroenterology. 2005;128:164–8.
Cartin-Ceba R, Swanson K, Iyer V, Wiesner RH, Krowka MJ. Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension. Chest. 2011;139:109–14.
Provencher S, Herve P, Jais X, Lebrec D, Humbert M, Simonneau G, Sitbon O. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology. 2006;130:120–6.
Fallon MB, Krowka MJ, Brown RS, Trotter JF, Zacks S, Roberts KE, Shah VH, et al. Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology. 2008;135:1168–75.
Schenk P, Schoniger-Hekele M, Fuhrmann V, Madl C, Silberhumer G, Muller C. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology. 2003;125:1042–52.
Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: impact of liver transplantation. Hepatology. 2005;41:1122–9.
Conflict of interest
A. Ferlitsch: Consultant for Pejcl Medizintechnik, Austria; Boston Scientifc: Travel expenses; Boston Scientific, Cook Medical, Ferring: Sponsoring of dedicated meetings.
V. Fuhrmann: Forschungsunterstützung von den Firmen Actelion, Air Liquide und Vivisol.
T. Reiberger: Roche (speaking/teaching, travel grant), MSD (speaking/teaching, research grant), Phenex Pharma (research grant), Gilead Sciences (research grant, travel grant), Janssen (research grant).
Rest of the authors declare that there are no actual or potential conflicts of interest in relation to this article.
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
For the Austrian Society of Gastroenterology and Hepatology (ÖGGH)
Appendix
Appendix
Participants “Billroth II”, 2. ÖGGH-Consensus Conference “Portal Hypertension”, Palais Clam Gallas, Vienna 011011
Dr. Bernhard Angermayr | Landesklinikum St. Pölten, 2. Medizinische Abteilung |
Dr. Eva Brownstone | KA Rudolfstiftung, 4. Medizinische Abteilung |
Theresa Bucsics | Univ.-Klinik für Innere Medizin III, AKH |
Prim. Dr. Christian Datz | Krankenhaus Oberndorf, Abteilung Innere Medizin |
Dr. Arnulf Ferlitsch | Univ.-Klinik für Innere Medizin III, AKH |
PD Dr. Valentin Fuhrmann | Univ.-Klinik für Innere Medizin III, AKH |
Univ.-Prof. Dr. Ivo Graziadei | Klinische Abteilung für Gastroenterologie und Hepatologie, Medizinische Universität Innsbruck |
Dr. Evelyn Grilnberger | Otto Wagner Spital |
Prim. Dr. Michael Häfner | KH St. Elisabeth, Interne Abteilung |
Dr. Birgit Heinisch | Univ.-Klinik für Innere Medizin III, AKH |
Dr. Sadia Hoppe | KH Hietzing, I. Medizinische Abteilung |
Dr. Thomas Horvatits | Univ.-Klinik für Innere Medizin III, AKH |
Prim. Dr. Andreas Kirchgatterer | V. Interne Abteilung, Klinikum Wels |
Prim. Dr. Peter Knoflach | Klinikum Wels-Grieskirchen, Abteilung für Innere Medizin I |
Dr. Andreas Kopecky | Thermenklinikum Baden, Interne Abteilung |
Dr. Peter Kotlan | Ordination Markt Priestling |
Prof. Dr. Ludwig Kramer | Krankenhaus Hietzing, 1. Medizinische Abteilung mit Gastroenterologie |
Dr. Anna Kreil | Otto Wagner Spital |
Waltraud Leiss | Univ.-Klinik für Innere Medizin III, AKH |
Dr. Simone Luszczak | Landesklinikum St. Pölten, 2. Medizinische Abteilung |
Prim. Dr. Christian Madl | KA Rudolfstiftung, 4. Medizinische Abteilung |
Dr. Andreas Maieron | Krankenhaus St. Elisabeth Linz, 4. Interne Abteilung |
Dr. Ilona Marszalek | Ordination Dr. Biowski-Frotz, Wien |
Prof. Dr. Christian Müller | Univ.-Klinik für Innere Medizin III, AKH |
Dr. Roland Nömeyer | Klinikum Wels-Grieskirchen, Abteilung für Innere Medizin I |
Dr. Julia Palkovits | Krankenhaus Hietzing, 1. Medizinische Abteilung mit Gastroenterologie |
Dr. Berit Anna Payer | Univ.-Klinik für Innere Medizin III, AKH |
Prof. Dr. Markus Peck-Radosavljevic | Univ.-Klinik für Innere Medizin III, AKH |
Prim. Dr. Johann Pidlich | Thermenklinikum Baden, Interne Abteilung |
Dr. Csilla Putz-Bankuti | Universitätsklinik für Innere Medizin, LKH Graz |
Dr. Thomas Reiberger | Univ.-Klinik für Innere Medizin III, AKH |
Dr. Birgit Reinhart | |
Dr. Karoline Reinhart | Univ.-Klinik für Innere Medizin III, AKH |
Dr. Petra Salzl | Univ.-Klinik für Innere Medizin III, AKH |
Dr. Monika Schmid | Univ.-Klinik für Innere Medizin III, AKH |
Dr. Christiane Schrutka | KA Rudolfstiftung, 4. Medizinische Abteilung |
Dr. Bernhard Stadler | Klinikum Wels-Grieskirchen |
Prof. Dr. Rudolf Stauber | Medizinische Universität Graz, Abteilung Gastroenterologie und Hepatologie |
Dr. Philipp Steininger | Krankenhaus St. Elisabeth Wien, Interne Abteilung |
Prof. Dr. Rudolf Steininger | Universitätsklinik für Chirurgie, Medizinische Uni Wien |
Prim. Dr. Siegfried Thurnher | Krankenhaus Barmherzige Brüder Wien, Radiologie und Nuklearmedizin |
Prof. Dr. Michael Trauner | Univ.-Klinik für Innere Medizin III, AKH |
Prof. Dr. Barbara Tribl | Univ.-Klinik für Innere Medizin III, AKH |
Dr. Gregor Ulbrich | Krankenhaus Hietzing, 1. Medizinische Abteilung mit Gastroenterologie |
Prim. Prof. Dr. Wolfgang Vogel | Klinische Abteilung für Gastroenterologie und Hepatologie, Medizinische Universität Innsbruck |
Dr. Martina Wichlas | KH Barmherzige Brüder, II. Medizinische Abteilung |
Dr. Afrodite Zendeli | KH Barmherzige Brüder, II. Medizinische Abteilung |
Prof. Dr. Heinz Zoller | Klinische Abteilung für Gastroenterologie und Hepatologie, Medizinische Universität Innsbruck |
Rights and permissions
About this article
Cite this article
Peck-Radosavljevic, M., Angermayr, B., Datz, C. et al. Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). Wien Klin Wochenschr 125, 200–219 (2013). https://doi.org/10.1007/s00508-013-0337-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00508-013-0337-z
Keywords
- Ascites
- Variceal bleeding
- TIPS
- Hepatorenal syndrome
- Hepatopulmonary syndrome
- Portopulmonary hypertension
- Budd-Chiari Syndrome
- Somatostatin
- Terlipressin
- Carvedilo